Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.58 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.57 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.57 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11003495 | 0.90 | KDM4E (0.69) | CACNA1CCACNA1FCACNA1DCACNA1SKDM4E | |
| SCHEMBL11007562 | 0.89 | KDM4E (0.57) | CYP1A2CYP3A4ADORA3MAPTCYP2C9 | |
| SCHEMBL11008392 | 0.89 | KDM4E (0.52) | CYP1A2CYP3A4ADORA3MAPTCYP2C9 | |
| SCHEMBL24117078 | 0.88 | CACNA1C (0.48) | CYP1A2CYP3A4ADORA3MAPTCYP2C9 | |
| SCHEMBL30266638 | 0.88 | CACNA1C (0.48) | CYP1A2CYP3A4ADORA3MAPTCYP2C9 | |
| SCHEMBL9637819 | 0.87 | KDM4E (0.58) | CYP1A2CYP3A4ADORA3MAPTCYP2C9 | |
| SCHEMBL11002812 | 0.86 | KDM4E (0.59) | CACNA1CTSHRCACNA1FCACNA1DCACNA1S | |
| SCHEMBL10830322 | 0.86 | KDM4E (0.59) | CYP1A2CYP3A4ADORA3MAPTCYP2C9 | |
| SCHEMBL11003525 | 0.86 | ALDH1A1 (0.56) | MAPTCACNA1CMEN1KMT2ACACNA1F | |
| SCHEMBL11008926 | 0.86 | KDM4E (0.58) | CACNA1CCACNA1FCACNA1DCACNA1SKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021255608-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4- B]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021255607-A1 | METHYL 2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATES AND METHYL 2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATES AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| US-20210395261-A1 | METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210387995-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-12-16 | — | — | US | disclosed |
| US-5026714-A | Novel 1-alkyl-substituted 1,4-dihydropyridinelactone anti-diabetics | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-25 | — | — | US | disclosed |
| US-4567268-A | Process for preparation of certain tetrahydrofuro[3,4-b]pyridines | MERCK & CO., INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4532248-A | Administering 1,4-dihydropyridine derivative exhibiting positive inotropic activity | BAYER AKTIENGESELLSCHAFT (DE) | 1985-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395261-A1 | METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS | CACNA1D, CACNA1B, CACNA1S | CYP1A2 1056/4885CYP3A4 1334/4885ADORA3 2163/4885 |
| US-20210387995-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | CACNA1D, CACNA1I, CACNA1S | CYP1A2 730/4885CYP3A4 886/4885ADORA3 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.